Fisher Scientific International Inc.'s (FSH) Second-Quarter Sales And Earnings Reach All-Time High; Company Completes Acquisition Of McKesson BioServices (MCK) And Announces Acquisitions Of Lancaster Laboratories And Cellomics, Inc. 
10/19/2005 5:09:05 PM

HAMPTON, N.H.--(BUSINESS WIRE)--Aug. 3, 2005--Fisher Scientific International Inc. (NYSE: FSH), a world leader in serving science, today reported record sales and earnings for the second quarter ended June 30, 2005, reflecting strong demand from healthcare customers and continued growth in sales of scientific products and services. "We concluded the first half of the year on a strong note -- setting new records for both sales and earnings," said Paul M. Montrone, chairman and chief executive officer. "Our scientific research and healthcare business segments performed well, and our integration of the Apogent businesses is on track. In addition to the acquisition of McKesson BioServices, which we completed last week, we have signed definitive agreements to acquire two other companies that will further expand our pharmaceutical service offering and enhance our portfolio of products for the life-science marketplace."